(unaudited)
Financial performance in the three months ended March 31, 2009
(Comparative figures for the same period last year are shown in brackets)
- Organic growth in vaccine sales for the first three months of the year was 14%
- Revenue in Q1 was DKK 493 million (445)
- Operating profit before depreciations and amortization (EBITDA) was DKK 96
million (66)
- Operating profit (EBIT) for Q1 increased by 72% organically to DKK 77 million
(45)
- Net profit for the period was DKK 55 million (25)
Outlook for 2009 unchanged
For the 2009 financial year, ALK retains its forecast of organic growth in
allergy vaccine sales of 10% or more and a substantial increase in operating
profit. The EBITDA forecast is retained at a minimum of DKK 230 million, and
the EBIT forecast is retained at a minimum of DKK 140 million in 2009.
Hørsholm, May 1, 2009
ALK-Abelló A/S
Contact:
Jens Bager, President and CEO, tel +45 4574 7576.
ALK holds a conference call for analysts and investors today at 1.00 p.m. (CET)
at which Jens Bager, President and CEO, and Jutta of Rosenborg, CFO, will
review the results. Danish participants must call in on tel +45 7026 5040
before 12.55 p.m. (CET), and international participants must call in on tel +44
208 817 9301 before 12.55 p.m. (CET). The conference call will also be webcast
on our website: www.alk-abello.com, where the related presentation will be
available shortly before the conference call begins.
